Pharmaceutical composition, application thereof and method for improving storage stability of pharmaceutical composition
By using alkyl glycoside compounds such as DDM in the GLP-1 receptor agonist pharmaceutical composition, the problem of poor stability of the pharmaceutical composition during storage is solved, and the effect of significantly improving the physical stability of the pharmaceutical composition is achieved.
Patent Information
- Application Number
- CN202310524629.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-10
- Publication Date
- 2024-11-12
AI Technical Summary
The existing GLP-1 receptor agonist pharmaceutical compositions are prone to form fibrous substances during storage, resulting in poor stability and inability to store for a long time.
Using alkyl glycoside compounds such as n-dodecyl β-D-maltoside (DDM) as surfactants to improve the physical stability of pharmaceutical compositions, especially when used in liquid preparations, GLP-1 is significantly improved Stability of receptor agonists.
By adding alkyl glycoside compounds such as DDM, fibrosis of GLP-1 receptor agonist is inhibited, the storage stability of the pharmaceutical composition is significantly improved, and the stability requirements of compound preparations as multi-dose water injection pharmaceutical compositions are met. .
Smart Images

Figure CN118924882A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedicine, and more specifically, the present application relates to a pharmaceutical composition containing a GLP-1 receptor agonist, a method for improving the storage stability of the pharmaceutical composition, and a use of the pharmaceutical composition in preparing a drug. Background Art
[0002] About 120 million people in the world suffer from diabetes. Exogenous insulin is mainly used to treat diabetes. Insulin is the only hormone in the body that lowers blood sugar and promotes the synthesis of glycogen, fat and protein. Glargine insulin is an analog of human insulin and can be obtained by recombinant DNA technology. After glargine insulin is injected into the subcutaneous tissue, the fine deposits formed by the neutralization of the acidic solution can continuously release a small amount of glargine insulin, thereby obtaining a predictable, long-lasting, stable, and peak-free blood drug concentration / time characteristic.
[0003] Glucagon-like peptide 1 (hereinafter referred to as GLP-1) is an incretin secretion peptide with the following physiological effects: promoting insulin secretion in a glucose-dependent manner, thereby reducing the risk of hypoglycemia; promoting insulin synthesis in the body, promoting the differentiation and generation of β cells, inhibiting the release of glucagon, inhibiting gastric emptying and food intake impulses, and increasing the sensitivity of insulin receptors. It has been clinically proven to have the advantages of lowering blood sugar, reducing weight, and increasing cardiovascular benefits.
[0004] The combined use of basal insulin and GLP-1 receptor agonists can fully utilize the complementary clinical advantages of the two, such as lowering blood sugar, reducing weight, reducing the risk of hypoglycemia and insulin resistance, etc. Premixed preparations containing basal insulin and GLP-1 are a simpler way of administration and there is a huge market demand.
[0005] However, the pharmaceutical compositions using GLP-1 receptor agonists still need further research. Summary of the invention
[0006] The present invention aims to solve at least one of the above technical problems to a certain extent or at least provide a useful commercial option. To this end, one object of the present invention is to propose a novel pharmaceutical composition comprising a GLP-1 receptor agonist. This pharmaceutical composition can improve the stability of the GLP1 receptor agonist in the pharmaceutical composition.
[0007] The present invention is accomplished based on the following findings of the inventors:
[0008] The inventors of the present invention found that the preparations of GLP-1 receptor agonists, especially liquid preparations, are prone to form fibrous substances during storage, and thus cannot be stored for a long time. Through extensive research by the inventors, it was unexpectedly found that this problem can only be solved by changing the surfactant. In particular, the inventors continued to screen the types of surfactants and unexpectedly obtained that alkyl glycoside compounds such as n-dodecyl β-D-maltoside (DDM) can greatly improve the stability of premixed preparations when applied to liquid preparations, especially water injection preparations, especially the physical stability of GLP-1 receptor agonists such as GLP-1 or GLP-1 analogs, and further found that even if the GLP-1 receptor agonist is used in combination with insulin or its analogs or derivatives, alkyl glycoside compounds such as n-dodecyl β-D-maltoside (DDM) also give the pharmaceutical composition outstanding physical stability, so that alkyl glycoside compounds such as n-dodecyl β-D-maltoside (DDM) can meet the stability requirements of compound preparations as multi-dose water injection pharmaceutical compositions. Generally speaking, alkyl glycoside compounds such as DDM are usually used as transmucosal absorption enhancers for peptides, proteins and small molecules. The applicant unexpectedly discovered and pioneered the application of alkyl glycoside compounds such as DDM in the formulation of aqueous injection preparations, which greatly improved the stability of premixed preparations, especially the physical stability of GLP-1, thereby meeting the stability requirements of compound preparations as multi-dose aqueous injection drug compositions, thereby completing the present invention.
[0009] Therefore, in the first aspect of the present invention, the present application proposes a pharmaceutical composition, which contains: an active ingredient, wherein the active ingredient includes a GLP-1 receptor agonist; and a surfactant, wherein the surfactant includes an alkyl glycoside compound.
[0010] According to the embodiments of the present application, by adopting alkyl glycoside compounds such as DDM, the formation of GLP-1 fibrillation in a pharmaceutical composition containing a GLP-1 receptor agonist such as GLP-1 or its analogs or derivatives can be inhibited, thereby improving the physical stability, and alkyl glycoside compounds such as DDM are significantly superior to other types of surfactants.
[0011] In the second aspect of the present application, the present application also proposes a method for improving the storage stability of a pharmaceutical composition, wherein the pharmaceutical composition contains a GLP-1 receptor agonist. According to an embodiment of the present application, the method comprises adding an alkyl glycoside compound to the pharmaceutical composition.
[0012] In the third aspect of the present application, the present application also proposes the use of the above-mentioned pharmaceutical composition in the preparation of a drug, wherein the drug is used for: (i) preventing and / or treating diabetes, and / or reducing HbA1C; (ii) delaying or preventing the progression of diabetes, delaying the progression of impaired glucose tolerance to type 2 diabetes requiring insulin, delaying or preventing insulin resistance, and / or delaying the progression of type 2 diabetes not requiring insulin to type 2 diabetes requiring insulin; (iii) improving β-cell function, and / or restoring β-cell glucose sensitivity; (iv) preventing and / or treating eating disorders; reducing gastric motility; delaying gastric emptying; (v) preventing and / or treating comorbidities of obesity; (vi) preventing and / or treating diabetic complications; and / or (vii) preventing and / or treating cardiovascular diseases.
[0013] Additional aspects and advantages of the present invention will be given in part in the following description and in part will be obvious from the following description, or will be learned through practice of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0014] The above and / or additional aspects and advantages of the present invention will become apparent and easily understood from the description of the embodiments in conjunction with the following drawings, in which:
[0015] Figure 1 The ThT test results of the insulin glargine / GLP-1 compound preparation according to one embodiment of the present invention are shown;
[0016] Figure 2 The ThT test results of the benaglutide stock solution according to one embodiment of the present invention are shown;
[0017] Figure 3 The ThT test results of benaglutide formulations without and with different concentrations of DDM according to one embodiment of the present invention are shown;
[0018] Figure 4 The ThT test results of the insulin glargine / GLP-1 compound DDM preparation containing different antibacterial agents according to one embodiment of the present invention are shown;
[0019] Figure 5 shows the ThT test results of the insulin glargine / GLP-1 compound preparation according to one embodiment of the present invention; and
[0020] Figures 6 to 8 The figure shows the effects of GLP-1 and polypeptides of similar structures (sample number: 988927) and GLP-1 / GIP dual agonist (sample number: P13) according to an embodiment of the present invention on the physical stability of the test samples in the presence of 0.1% DDM and in the absence of DDM. DETAILED DESCRIPTION
[0021] Embodiments of the present invention are described in detail below. The embodiments described below with reference to the accompanying drawings are exemplary and are intended to be used to explain the present invention, but should not be construed as limiting the present invention.
[0022] definition
[0023] Unless otherwise specified, the term "active ingredient" as used herein refers to a substance or combination of substances in a drug that produces a therapeutic or preventive effect. For example, according to the embodiments of the present application, the active ingredient used may be one or more GLP-1 receptor agonists, or insulin or its analogs or derivatives may be additionally added to the pharmaceutical composition, so that the pharmaceutical composition can exert the desired therapeutic or preventive effect when applied to the subject of administration.
[0024] Unless otherwise specified, the term "surfactant" as used herein refers to a class of chemical substances that can reduce the surface tension and interfacial tension of liquids, usually composed of hydrophobic groups and hydrophilic groups. Surfactants are usually used to regulate the solubility, stability and bioavailability of drugs, thereby affecting the absorption, distribution, metabolism and excretion of drugs.
[0025] Unless otherwise specified, the term "alkyl glycoside compound" used in this article is a class of surfactants composed of a sugar group and an alkyl chain, which has good surface activity and biodegradability. These compounds are usually obtained by enzyme-catalyzed reactions of sugars and fatty alcohols at a certain temperature and pressure. Since the molecular structure of alkyl glycoside compounds contains both hydrophobic groups and hydrophilic groups, they have properties similar to traditional surfactants. Among them, the alkyl chain is hydrophobic and can interact with non-polar solvents; while the sugar group is hydrophilic and can interact with water. The inventors of the present invention have found that when preparing the pharmaceutical composition of the present application, alkyl glycoside compounds can be used as non-ionic surfactants, which can be used to promote the stability, solubility and bioavailability of drugs, and can also reduce the toxicity and irritation of the preparation, and improve the safety and tolerability of the drug.
[0026] Unless otherwise specified, the term "analog" as used in this article refers to a molecule that is similar to the original molecular structure but has the same or different chemical properties. For example, in drug research, researchers may design and synthesize a series of compounds that are structurally similar to a known drug molecule, but have different chemical groups or substituents, thereby changing its pharmacological properties, such as absorption, metabolism, drug efficacy, etc. These analogs may have better pharmacological properties or toxicological properties, and therefore have the potential for further development as drugs. More specifically, in the present application, "analogs" are used to represent such peptides, wherein one or more amino acid residues of the parent peptide have been replaced by other amino acid residues and / or wherein one or more amino acid residues of the parent peptide have been missing and / or wherein one or more amino acid residues have been added to the parent peptide. Such addition usually occurs at the N-terminal or C-terminal or both ends of the parent peptide. According to specific embodiments, an "analog" in the present application is generally a peptide in which 6 or fewer amino acids of the parent peptide have been substituted and / or added and / or deleted, more preferably a peptide in which 3 or fewer amino acids of the parent peptide have been substituted and / or added and / or deleted, and most preferably a peptide in which one amino acid of the parent peptide has been substituted and / or added and / or deleted.
[0027] Unless otherwise specified, the term "derivative" as used in this article refers to a new molecule obtained by chemical modification or transformation of an original molecule. For example, in drug research, researchers may start from a known drug molecule and synthesize a series of new compounds by changing, replacing or modifying its structure. These new molecules are called derivatives of the drug molecule. Derivatives may have better pharmacological properties, better safety or lower side effects, and therefore also play an important role in drug development. Specifically, in this application, "derivative" is used to represent peptides in which one or more amino acid residues of the parent peptide have been introduced with substituents, and typical substituents may be amides, sugars, alkyls, acyl groups, esters, pegylation, etc.
[0028] Unless otherwise specified, the term "GLP-1 receptor agonists" used in this article refers to a class of drugs for treating diabetes, which promote insulin secretion and inhibit the production and release of glucose by simulating the biological activity of glucagon-like polypeptide-1 (GLP-1), thereby helping to lower blood sugar levels. Among them, GLP-1 is a peptide hormone secreted by intestinal L cells and brainstem neurons, and has multiple biological functions, including suppressing appetite, stimulating insulin secretion, inhibiting glucose production and release, etc. GLP-1 receptor agonists can stimulate GLP-1 receptors, enhance insulin secretion, and inhibit the production and release of glucose. Due to its effectiveness in blood sugar control and good tolerability, GLP-1 receptor agonists have become one of the first-line drugs for the treatment of type 2 diabetes. In addition to diabetes treatment, GLP-1 receptor agonists are also being studied for the treatment of other fields such as obesity, cardiovascular disease and neurodegenerative diseases.
[0029] Unless otherwise specified, the term "treatment" as used in this article refers to the use of drugs to alleviate or cure a disease state, and "prevention" refers to the use of drugs to prevent the occurrence of a disease or reduce the possibility of the occurrence of a disease, which can be to prevent or delay the occurrence or progression of these diseases.
[0030] The present invention is accomplished based on the following findings of the inventors:
[0031] The inventors of the present invention found that the preparations of GLP-1 receptor agonists, especially liquid preparations, are prone to form fibrous substances during storage, and thus cannot be stored for a long time. Through extensive research by the inventors, it was unexpectedly found that this problem can only be solved by changing the surfactant. In particular, the inventors continued to screen the types of surfactants and unexpectedly obtained that alkyl glycoside compounds such as n-dodecyl β-D-maltoside (DDM) can greatly improve the stability of premixed preparations when applied to liquid preparations, especially water injection preparations, especially the physical stability of GLP-1 receptor agonists such as GLP-1 or GLP-1 analogs, and further found that even if the GLP-1 receptor agonist is used in combination with insulin or its analogs or derivatives, alkyl glycoside compounds such as n-dodecyl β-D-maltoside (DDM) also give the pharmaceutical composition outstanding physical stability, so that alkyl glycoside compounds such as n-dodecyl β-D-maltoside (DDM) can meet the stability requirements of compound preparations as multi-dose water injection pharmaceutical compositions. Generally speaking, alkyl glycoside compounds such as DDM are usually used as transmucosal absorption enhancers for peptides, proteins and small molecules. The applicant unexpectedly discovered and pioneered the application of alkyl glycoside compounds such as DDM in the formulation of aqueous injection preparations, which greatly improved the stability of premixed preparations, especially the physical stability of GLP-1, thereby meeting the stability requirements of compound preparations as multi-dose aqueous injection drug compositions, thereby completing the present invention.
[0032] In the first aspect of the present invention, the present application proposes a pharmaceutical composition comprising: an active ingredient, wherein the active ingredient includes a GLP-1 receptor agonist; and a surfactant, wherein the surfactant includes an alkyl glycoside compound.
[0033] According to the embodiments of the present application, by adopting alkyl glycoside compounds such as DDM, the formation of GLP-1 fibrillation in a pharmaceutical composition containing a GLP-1 receptor agonist such as GLP-1 or its analogs or derivatives can be inhibited, thereby improving the physical stability, and alkyl glycoside compounds such as DDM are significantly superior to other types of surfactants.
[0034] According to an embodiment of the present application, the active ingredient further includes insulin or insulin analogs. According to an embodiment of the present application, the insulin analogs that can be used include at least one of insulin lispro, insulin aspart, insulin glulisine, insulin glargine, insulin degludec and insulin detemir. According to a specific embodiment of the present application, based on the total weight of the pharmaceutical composition, the pharmaceutical composition contains 0.1 to 1% by weight of insulin or insulin analogs, and optionally, contains 0.1 to 0.4% by weight of insulin or insulin analogs, for example, contains 0.2 to 0.4% by weight of insulin or insulin analogs, for example, the pharmaceutical composition contains: 0.1% by weight of at least one of insulin lispro, insulin aspart, insulin glulisine, insulin glargine, insulin degludec and insulin detemir; 0.2% by weight of at least one of insulin lispro, insulin aspart, insulin glulisine, insulin glargine, insulin degludec and insulin detemir; 0.3% by weight of insulin lispro. 0.4% by weight of at least one of insulin lispro, insulin aspart, insulin glulisine, insulin glargine, insulin degludec and insulin detemir; 0.5% by weight of at least one of insulin lispro, insulin aspart, insulin glulisine, insulin glargine, insulin degludec and insulin detemir; 0.6% by weight of at least one of insulin lispro, insulin aspart, insulin glulisine, insulin glargine, insulin degludec and insulin detemir; 0.7% by weight of insulin lispro, insulin aspart, insulin glulisine, insulin glargine, insulin degludec and insulin detemir 0.8% by weight of at least one of insulin lispro, insulin aspart, insulin glulisine, insulin glargine, insulin degludec and insulin detemir; 0.9% by weight of at least one of insulin lispro, insulin aspart, insulin glulisine, insulin glargine, insulin degludec and insulin detemir; or 0.10% by weight of at least one of insulin lispro, insulin aspart, insulin glulisine, insulin glargine, insulin degludec and insulin detemir, especially containing 0.20% to 0.40% by weight of insulin or insulin analogs, such as 0.20% by weight of insulin or insulin analogs or derivatives; 0.21% by weight of islet 0.22% by weight of insulin or insulin analogs or derivatives; 0.23% by weight of insulin or insulin analogs or derivatives; 0.24% by weight of insulin or insulin analogs or derivatives; 0.25% by weight of insulin or insulin analogs or derivatives; 0.26% by weight of insulin or insulin analogs or derivatives; 0.27% by weight of insulin or insulin analogs or derivatives; 0.28% by weight of insulin or insulin analogs or derivatives; 0.29% by weight of insulin or insulin analogs or derivatives; 0.30% by weight of insulin or insulin analogs or derivatives; 0.31% by weight of insulin or insulin analogs or derivatives; 0.32% by weight of insulin or insulin analogs or derivatives; 0.33% by weight of insulin or insulin analogs or derivatives; 0.34% by weight of insulin or insulin analogs or derivatives; 0.35% by weight of insulin or insulin analogs or derivatives; 0.36% by weight of insulin or insulin analogs or derivatives; 0.37% by weight of insulin or insulin analogs or derivatives; 0.38% by weight of insulin or insulin analogs or derivatives; 0.39% by weight of insulin or insulin analogs or derivatives; 0.40% by weight of insulin or insulin analogs or derivatives. It should be noted that when the pharmaceutical composition is configured as a liquid preparation such as a premixed water injection preparation, the above "weight %" can also be expressed as "mg / ml", for example, containing 0.40% by weight of insulin or insulin analogs or derivatives can be replaced by containing 4.0mg / ml of insulin or insulin analogs or derivatives, which will not be repeated here. The inventors of the present application unexpectedly discovered that alkyl glycoside compounds such as DDM can not only improve the stability of GLP-1 receptor agonists, but also simultaneously improve the stability of GLP-1 receptor agonists and insulin or insulin analogs or derivatives.
[0035] According to an embodiment of the present application, the alkyl glycoside compound that can be applied to the technical solution of the present application contains: a sugar group, the sugar group includes at least one selected from glucose, maltose, sucrose and trehalose; an alkyl chain, the alkyl chain contains 10 to 16 carbon atoms; a connecting group, the connecting group is used to connect the sugar group and the alkyl chain, and the connecting group includes at least one selected from a glycosidic bond, a thioglycosidic bond and an amide bond. According to an embodiment of the present application, the alkyl chain contains 10 to 14 carbon atoms. This type of compound has a similar structure to DDM and is expected to have a similar effect of improving the stability of the pharmaceutical composition. According to an embodiment of the present application, the sugar group includes maltose or sucrose. According to an embodiment of the present application, the alkyl glycoside compound includes at least one of n-dodecyl β-D-maltoside (DDM), sucrose monododecanoate, and n-dodecyl β-D-maltoside, preferably n-dodecyl β-D-maltoside (DDM).Based on the total weight of the pharmaceutical composition, the pharmaceutical composition contains 0.05-0.50 weight% of an alkyl glycoside compound, for example, 0.05 weight% of an alkyl glycoside compound, 0.06 weight% of an alkyl glycoside compound, 0.07 weight% of an alkyl glycoside compound, 0.08 weight% of an alkyl glycoside compound, 0.09 weight% of an alkyl glycoside compound, 0.10 weight% of an alkyl glycoside compound, 0.11 weight% of an alkyl glycoside compound, 0.12 weight% of an alkyl glycoside compound, 0.13 weight% of an alkyl glycoside compound, 0.14 wt% of alkyl glycoside compounds, 0.15 wt% of alkyl glycoside compounds, 0.16 wt% of alkyl glycoside compounds, 0.17 wt% of alkyl glycoside compounds, 0.18 wt% of alkyl glycoside compounds, 0.19 wt% of alkyl glycoside compounds, 0.20 wt% of alkyl glycoside compounds, 0.21 wt% of alkyl glycoside compounds, 0.22 wt% of alkyl glycoside compounds, 0.23 wt% of alkyl glycoside compounds, 0.24 wt% of alkyl glycoside compounds, 0.25 wt% of alkyl glycoside compounds compounds, 0.26% by weight of alkyl glycoside compounds, 0.27% by weight of alkyl glycoside compounds, 0.28% by weight of alkyl glycoside compounds, 0.29% by weight of alkyl glycoside compounds, 0.30% by weight of alkyl glycoside compounds, 0.31% by weight of alkyl glycoside compounds, 0.32% by weight of alkyl glycoside compounds, 0.33% by weight of alkyl glycoside compounds, 0.34% by weight of alkyl glycoside compounds, 0.35% by weight of alkyl glycoside compounds, 0.36% by weight of alkyl glycoside compounds, 0.37% by weight of alkyl glycoside compounds, 0.38% by weight % of alkyl glycoside compounds, 0.39% by weight of alkyl glycoside compounds, 0.40% by weight of alkyl glycoside compounds, 0.41% by weight of alkyl glycoside compounds, 0.42% by weight of alkyl glycoside compounds, 0.43% by weight of alkyl glycoside compounds, 0.44% by weight of alkyl glycoside compounds, 0.45% by weight of alkyl glycoside compounds, 0.46% by weight of alkyl glycoside compounds, 0.47% by weight of alkyl glycoside compounds, 0.48% by weight of alkyl glycoside compounds, 0.49% by weight of alkyl glycoside compounds or 0.50% by weight of alkyl glycoside compounds.According to specific embodiments of the present application, optionally, the pharmaceutical composition contains 0.1 to 0.20 weight % of alkyl glycoside compounds, for example, 0.10 weight % of alkyl glycoside compounds, 0.11 weight % of alkyl glycoside compounds, 0.12 weight % of alkyl glycoside compounds, 0.13 weight % of alkyl glycoside compounds, 0.14 weight % of alkyl glycoside compounds, 0.15 weight % of alkyl glycoside compounds, 0.16 weight % of alkyl glycoside compounds, 0.17 weight % of alkyl glycoside compounds, 0.18 weight % of alkyl glycoside compounds, 0.19 weight % of alkyl glycoside compounds or 0.20 weight % of alkyl glycoside compounds. It should be noted that, when the pharmaceutical composition is configured as a liquid preparation such as a premixed aqueous injection preparation, the above "weight %" can also be expressed as "mg / ml". For example, a liquid containing 0.20 weight % of an alkyl glycoside compound can be replaced with a liquid containing 2.0 mg / ml of an alkyl glycoside compound.
[0036] According to an embodiment of the present application, the GLP-1 receptor agonist is a polypeptide agonist. Optionally, the GLP-1 receptor agonist may also have a GIP agonist function. In other words, a dual agonist may be used.
[0037] According to a specific embodiment of the present application, the GLP-1 receptor agonist includes at least one selected from the following: GLP-1, a GLP-1 analog or a derivative thereof; and a truncated GLP-1 fragment or an analog or derivative thereof. Specifically, GLP-1 analogs include Exendin-4 and its analogs and derivatives. According to other embodiments of the present application, the GLP-1 receptor agonist includes at least one selected from the following: liraglutide, exenatide, lixisenatide, albiglutide, benaglutide, dulaglutide, semaglutide, pepramotetide, tirpotide, preferably benaglutide. Preferably, the active ingredient includes a combination of benaglutide and insulin glargine.
[0038] Specifically, the "GLP-1 receptor agonist" that can be applied to the present application refers to some polypeptides, which include natural, extended or truncated GLP-1 polypeptides (such as GLP-1 (7-37) OH / NH2, GLP-1 (7-36) OH / NH2, GLP-1 (7-35) OH / NH2), GLP-1 fragments, GLP-1 analogs and their derivatives. GLP-1 receptor agonists also include dual or multiple agonists based on the GLP-1 sequence, such as GLP-1 / GIP dual agonists. The GLP-1 compounds of the present invention have the ability to bind to the GLP-1 receptor and initiate a signal transduction pathway that leads to insulinotropic activity. GLP-1 and GLP-1 analogs may have a C-terminal free carboxyl group or a C-terminal amide group. For example, the GLP-1 analog can be a recombinant human GLP-1 (7-36) peptide having the following sequence: His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg, referred to as beinaglutide in this specification, beinaglutide has a molecular formula of C149H225N39O46, and a molecular weight of 3,298.7. Except for endogenous amidation, beinaglutide is substantially identical to the active form of GLP-1 in vivo, wherein the NH2 of the natural form is replaced by an OH group in the recombinant peptide. Beinaglutide includes a free C-terminal carboxyl group.
[0039] According to a specific embodiment of the present application, the GLP-1 receptor agonist is a polypeptide having the following sequence: XHXEGTXTSDXSXXXEXXAXXXFIXWLVXGXX (SEQ ID NO: 1), wherein:
[0040] X at position 6 means: R, or missing;
[0041] The X in the 8th position means: A, G, V, L, I, S or T;
[0042] The 12th position X means: F, W or Y;
[0043] The 16th position X represents: V, S, W, I, L, K, F or Y;
[0044] The X in the 18th position means: S, W, Y, F, K, I, L or V;
[0045] The 19th position X means: Y, W or F;
[0046] The 20th position X means: L, F, Y or W;
[0047] The X at the 22nd position represents: G, E, D, Q, N, K, R or C;
[0048] The 23rd position X means: H, D, K, E or Q;
[0049] The 25th position X represents: A, V, I or L;
[0050] The 26th position X represents: K, R, Q, or N;
[0051] X at position 27 represents: A, E, H, F, Y, W, R, I or K;
[0052] X at position 30 means: A, E, D, S or H;
[0053] X at position 33 means: V or I;
[0054] The 34th position X represents: K, R, Q, or N;
[0055] X at position 36 represents: R, R-NH2, K, or K-NH2;
[0056] X at position 37 means: G, K, R, T, S, E, D, W, Y, F, H or missing.
[0057] In addition, according to another specific embodiment of the present application, the GLP-1 receptor agonist is a polypeptide having the following sequence: XXXGTXXXXXSKQXEEEAVXLXXXXLKNGGXXXXXXXXX (SEQ ID NO: 2)
[0058] Wherein, the first X represents H, R, Y or EL;
[0059] The second X is represented by S, G, A or T;
[0060] The third X is represented by D or E;
[0061] The 6th position X is represented by F or Y;
[0062] The 7th position X is represented by T, Y or S;
[0063] The 8th position X is represented by S or Y;
[0064] The 9th position X represents D or E;
[0065] The 10th X represents L or I;
[0066] The 14th X represents L, I, V or M;
[0067] The 20th X is represented by R or K;
[0068] The 22nd position X is F or Y;
[0069] X at position 23 represents I, V, L or M;
[0070] The 24th X represents E or D;
[0071] The 25th X is W, F or Y;
[0072] X at position 31 is represented by P or missing;
[0073] X at position 32 is represented by S or missing;
[0074] X at position 33 is represented by S or missing;
[0075] X at position 34 represents G or is missing;
[0076] X at position 35 is represented by A or is missing;
[0077] X at position 36 is represented by P or missing;
[0078] X at position 37 is represented by P or missing;
[0079] X at position 38 is represented by P or missing;
[0080] X at position 39 represents S, R or absence.
[0081] Those skilled in the art will appreciate that the pharmaceutical composition of the present application may also contain other pharmaceutically acceptable excipients, such as antibacterial agents and pharmaceutically acceptable dissolution promoters and zinc ions.
[0082] For example, according to an embodiment of the present invention, the present application has developed a novel premixed preparation containing a GLP-1 agonist and insulin, and these premixed preparations can be used to treat diseases such as non-insulin-dependent diabetes and insulin-dependent diabetes. The premixed preparation is a multi-dose water injection pharmaceutical composition that can meet the requirements of the shelf life. According to an embodiment of the present application, the preparation may contain a GLP-1 receptor agonist, insulin or its analogs or derivatives, an antibacterial agent, a pharmaceutically acceptable solubilizing agent, a novel surfactant DDM and zinc ions. Wherein, the pH value of the premixed preparation is 4.0 to 5.0.
[0083] Thus, the inventors found that DDM can improve the storage stability of a drug combination comprising a GLP-1 agonist and insulin. Specifically, by adding an appropriate amount of DDM to the preparation, the physical stability of the GLP-1 agonist in the drug combination can be improved, thereby improving the storage stability of the preparation.
[0084] Generally speaking, the stability of GLP-1 receptor agonists may be impaired by a variety of stresses. These stresses include pH, temperature, light, oscillation, and gas-liquid interface. The inventors of the present application have found that a series of commonly used surfactants are not beneficial to the chemical or physical integrity of premixes containing insulin and GLP-1 receptor agonists. For example: polysorbate 20, polysorbate 80, poloxamer 188, hydroxypropyl beta-cyclodextrin, and various amino acids. For this reason, the inventors of the present application unexpectedly found that even if these common surfactants are not used in the pharmaceutical composition of the present application, the technical effects of the present invention can be achieved. Therefore, the pharmaceutical composition according to the present invention preferably does not contain these components. Thus, according to an embodiment of the present application, the pharmaceutical composition does not contain any one of the following surfactants: polysorbate 20, polysorbate 80, poloxamer 188, hydroxypropyl beta-cyclodextrin, and amino acids, and optionally, the surfactant only includes alkyl glycoside compounds. In other words, the surfactant according to the embodiment of the present application is composed of alkyl glycoside compounds.
[0085] According to an embodiment of the present application, the pharmaceutical composition is a liquid preparation, preferably a premixed aqueous injection preparation. According to an embodiment of the present application, the pharmaceutical composition of the present invention is configured as a premixed preparation that is an injectable composition, preferably for subcutaneous injection.
[0086] The composition according to the present invention may contain one or more buffer salts commonly used for pH adjustment, such as 10-20 mM acetate or hydrochloride. According to the embodiments of the present application, the composition according to the present invention may not use buffer salts.
[0087] The composition according to the present invention may contain zinc ions. The concentration of zinc ions ranges from 10 micrograms / ml to 50 micrograms / ml, more preferably ranges from 20 to 40 micrograms / ml.
[0088] The pharmaceutical composition according to the present invention may include a suitable solubilizing agent. The term "solubilizing agent" used herein refers to a solvent that can improve solubility and assist or enhance dissolution ability. It can be understood by those skilled in the art that the meaning of the term "solubilizing agent" used herein does not include surfactants. According to an embodiment of the present application, a suitable solubilizing agent is, for example, glycerol, mannitol, propylene glycol or a combination thereof, and the solubilizing agent content is 10 to 50 mg / ml based on the total volume of the pharmaceutical composition, for example, the solubilizing agent content is 15 mg / ml, 20 mg / ml, 25 mg / ml, 30 mg / ml, 35 mg / ml, 40 mg / ml, 45 mg / ml. According to the composition of the present invention, glycerol is preferably a solubilizing agent, and the glycerol content is 10 to 25 mg / ml based on the total volume of the pharmaceutical composition, for example, the glycerol content is 12 mg / ml, 14 mg / ml, 16 mg / ml, 18 mg / ml, 20 mg / ml, 22 mg / ml, 24 mg / ml.
[0089] According to an embodiment of the present application, the pharmaceutical composition may contain an antibacterial agent. Optionally, the antibacterial agent includes at least one of a phenolic compound, an aromatic alcohol compound, phenoxyethanol and a chlorohydrin compound. Preferably, the antibacterial agent includes at least one of phenol, metacresol, benzyl alcohol, phenoxyethanol and chlorobutanol. According to an embodiment of the present application, the antibacterial agent that can be used is phenol. For example, the pharmaceutical composition contains 2.0 to 4.0 mg / ml of phenol, for example, the pharmaceutical composition contains 2.0 mg / ml of phenol, the pharmaceutical composition contains 2.1 mg / ml of phenol, the pharmaceutical composition contains 2.2 mg / ml of phenol, the pharmaceutical composition contains 2.3 mg / ml of phenol, the pharmaceutical composition contains 2.4 mg / ml of phenol, the pharmaceutical composition contains 2.5 mg / ml of phenol, the pharmaceutical composition contains 2.6 mg / ml of phenol, the pharmaceutical composition contains 2.7 mg / ml of phenol, the pharmaceutical composition contains 2.8 mg / ml of phenol. l of phenol, a pharmaceutical composition containing 2.9 mg / ml of phenol, a pharmaceutical composition containing 2.10 mg / ml of phenol, a pharmaceutical composition containing 2.11 mg / ml of phenol, a pharmaceutical composition containing 2.12 mg / ml of phenol, a pharmaceutical composition containing 2.13 mg / ml of phenol, a pharmaceutical composition containing 2.14 mg / ml of phenol, a pharmaceutical composition containing 2.15 mg / ml of phenol, a pharmaceutical composition containing 2.16 mg / ml of phenol, a pharmaceutical composition containing 2.17 mg / ml of phenol, a pharmaceutical composition containing 2.18 mg / ml of phenol, a pharmaceutical composition containing 2.19 mg / ml of phenol, pharmaceutical composition containing 2.20mg / ml of phenol, pharmaceutical composition containing 2.21mg / ml of phenol, pharmaceutical composition containing 2.22mg / ml of phenol, pharmaceutical composition containing 2.23mg / ml of phenol, pharmaceutical composition containing 2.24mg / ml of phenol, pharmaceutical composition containing 2.25mg / ml of phenol, pharmaceutical composition containing 2.26mg / ml of phenol, pharmaceutical composition containing 2.27mg / ml of phenol, pharmaceutical composition containing 2.28mg / ml of phenol, pharmaceutical composition containing 2.29mg / ml of phenol, pharmaceutical composition containing There is 2.30 mg / ml of phenol, a pharmaceutical composition contains 2.31 mg / ml of phenol, a pharmaceutical composition contains 2.32 mg / ml of phenol, a pharmaceutical composition contains 2.33 mg / ml of phenol, a pharmaceutical composition contains 2.34 mg / ml of phenol, a pharmaceutical composition contains 2.35 mg / ml of phenol, a pharmaceutical composition contains 2.36 mg / ml of phenol, a pharmaceutical composition contains 2.37 mg / ml of phenol, a pharmaceutical composition contains 2.38 mg / ml of phenol, a pharmaceutical composition contains 2.39 mg / ml of phenol or a pharmaceutical composition contains 2.40 mg / ml of phenol.
[0090] According to the embodiments of the present application, the pharmaceutical composition may contain 0.1 to 10 mg / mL of a GLP-1 receptor agonist, preferably 0.1 to 2.5 mg / mL of a GLP-1 receptor agonist, and may optionally contain 0.1 to 1 mg / mL of a GLP-1 receptor agonist, for example, 0.1 mg / mL of a GLP-1 receptor agonist, 0.2 mg / mL of a GLP-1 receptor agonist, 0.3 mg / mL of a GLP-1 receptor agonist, 0.4 mg / mL of a GLP-1 receptor agonist, 0.5 mg / mL of a GLP-1 receptor agonist, 0.6 mg / mL of a GLP-1 receptor agonist, 0.7 mg / mL of a GLP-1 receptor agonist, 0.8 mg / mL of a GLP-1 receptor agonist, 0.9 mg / mL of a GLP-1 receptor agonist, or 1.0 mg / mL of a GLP-1 receptor agonist.
[0091] According to the embodiments of the present application, the pH of the liquid preparation is 3.0 to 5.0, for example, the pH of the liquid preparation is 3.0, the pH of the liquid preparation is 3.1, the pH of the liquid preparation is 3.2, the pH of the liquid preparation is 3.3, the pH of the liquid preparation is 3.4, the pH of the liquid preparation is 3.5, the pH of the liquid preparation is 3.6, the pH of the liquid preparation is 3.7, the pH of the liquid preparation is 3.8, the pH of the liquid preparation is 3.9, the pH of the liquid preparation is 4.0, the pH of the liquid preparation is 4.1, the pH of the liquid preparation is 4.2, the pH of the liquid preparation is The pH of the liquid preparation is 4.3, the pH of the liquid preparation is 4.4, the pH of the liquid preparation is 4.5, the pH of the liquid preparation is 4.6, the pH of the liquid preparation is 4.7, the pH of the liquid preparation is 4.8, the pH of the liquid preparation is 4.9, the pH of the liquid preparation is 5.0, the pH of the liquid preparation is 5.1, the pH of the liquid preparation is 5.2, the pH of the liquid preparation is 5.3, the pH of the liquid preparation is 5.4, the pH of the liquid preparation is 5.5, the pH of the liquid preparation is 5.6, the pH of the liquid preparation is 5.7, the pH of the liquid preparation is 5.8, the liquid The pH of the liquid preparation is 5.9, the pH of the liquid preparation is 6, the pH of the liquid preparation is 6.1, the pH of the liquid preparation is 6.2, the pH of the liquid preparation is 6.3, the pH of the liquid preparation is 6.4, the pH of the liquid preparation is 6.5, the pH of the liquid preparation is 6.6, the pH of the liquid preparation is 6.7, the pH of the liquid preparation is 6.8, the pH of the liquid preparation is 6.9, the pH of the liquid preparation is 7, the pH of the liquid preparation is 7.1, the pH of the liquid preparation is 7.2, the pH of the liquid preparation is 7.3, the pH of the liquid preparation is 7.4, the pH of the liquid preparation is The pH of the liquid preparation is 7.5, the pH of the liquid preparation is 7.6, the pH of the liquid preparation is 7.7, the pH of the liquid preparation is 7.8, the pH of the liquid preparation is 7.9, the pH of the liquid preparation is 8, the pH of the liquid preparation is 8.1, the pH of the liquid preparation is 8.2, the pH of the liquid preparation is 8.3, the pH of the liquid preparation is 8.4, the pH of the liquid preparation is 8.5, the pH of the liquid preparation is 8.6, the pH of the liquid preparation is 8.7, the pH of the liquid preparation is 8.8, the pH of the liquid preparation is 8.9, and the pH of the liquid preparation is 9.0. Optionally, the insulin analog is glargine insulin, and the pH of the liquid preparation is 3.0 to 5.0. Optionally, the pH of the liquid preparation is 4.0 to 4.5.
[0092] According to an embodiment of the present application, the pharmaceutical composition further contains zinc ions. Optionally, the zinc ions can be provided by zinc chloride or zinc acetate. Optionally, the concentration of zinc ions is 1 to 100 micrograms / ml. Optionally, the concentration of zinc ions is 10 micrograms / ml to 50 micrograms / ml, for example, the concentration of zinc ions is 10 micrograms / ml, 15 micrograms / ml, 20 micrograms / ml, 25 micrograms / ml, 30 micrograms / ml, 35 micrograms / ml, 40 micrograms / ml, 45 micrograms / ml or 50 micrograms / ml. Optionally, the concentration of zinc ions is 20 to 40 micrograms / ml.
[0093] According to the examples of the present application, the pharmaceutical composition does not form foreign matter in the accelerated stability test at 25 degrees Celsius for 3 months, and the peptide content is not less than 93%, or even not less than 94%. The non-formation of foreign matter and the peptide content described here are determined by the method described in the general method in the examples.
[0094] In the second aspect of the present application, the present application also proposes a method for improving the storage stability of a pharmaceutical composition, wherein the pharmaceutical composition contains a GLP-1 receptor agonist. According to an embodiment of the present application, the method comprises adding an alkyl glycoside compound to the pharmaceutical composition.
[0095] According to an embodiment of the present application, the pharmaceutical composition may further include insulin or an insulin analog, and optionally, the insulin analog includes at least one of insulin lispro, insulin aspart, insulin glulisine, insulin glargine, insulin degludec and insulin detemir.
[0096] According to an embodiment of the present application, the alkyl glycoside compound includes at least one of n-dodecyl β-D-maltoside (DDM), sucrose monododecanoate, and n-dodecyl β-D-maltoside, preferably n-dodecyl β-D-maltoside (DDM).
[0097] It should be noted that those skilled in the art can understand that the features and technical effects described in the first aspect are also applicable to the second aspect and will not be elaborated here.
[0098] In the third aspect of the present application, the present application also proposes the use of the aforementioned pharmaceutical composition in the preparation of a medicament, wherein the medicament is used for: (i) preventing and / or treating diabetes, and / or for reducing HbA1C;
[0099] (ii) delay or prevent the progression of diabetes, delay the progression of impaired glucose tolerance to type 2 diabetes requiring insulin, delay or prevent insulin resistance, and / or delay the progression of type 2 diabetes not requiring insulin to type 2 diabetes requiring insulin; (iii) improve β-cell function, and / or restore β-cell glucose sensitivity; (iv) prevent and / or treat eating disorders; reduce gastric motility; delay gastric emptying; (v) prevent and / or treat comorbidities of obesity; (vi) prevent and / or treat diabetic complications; and / or (vii) prevent and / or treat cardiovascular disease.
[0100] The following examples are provided to better illustrate the claimed invention and the embodiments described herein, but these embodiments should not be construed as limiting the scope of the present invention. Unless otherwise specified, the specific materials listed in the following examples are for illustrative purposes only and are not intended to limit the present invention. It will be apparent to those skilled in the art that a variety of equivalents, changes and modifications can be made without departing from the scope of the present invention, and it should be understood that these equivalent embodiments will be included herein. In addition, all references cited in this application are incorporated herein by reference as if fully set forth herein.
[0101] Example
[0102] General approach
[0103] Unless otherwise specified, the relevant test methods are implemented in the following examples by the schemes listed below.
[0104] 1. ThT test
[0105] The ThT test is a commonly used method for monitoring protein fibril formation, in which thioflavin T (ThT) is a benzothiazole fluorescent dye that can bind to amyloid fibrils with high specificity and cause fluorescence enhancement after binding. The test uses the change in fluorescence intensity to measure the kinetics of protein fibril formation, and when the fluorescence intensity exceeds the set threshold, it can be used as a basis for fibril formation. Unless otherwise specified, in the embodiments of the present application, the set threshold is 3 times the initial value of the fluorescence intensity at the measurement point, that is, Tn / T1=3.
[0106] ThT test steps:
[0107] Experimental part:
[0108] 1. Sample preparation: Prepare the test sample according to the ThT test sample prescription list, take 500 μl of the test sample and mix it with 25 μl of 1 mM Thioflavin T aqueous solution, take 200 μl and add it to a black V-shaped 96-well plate (Eppendorf), set up 2 replicate wells for each sample (each sample will be assigned to 2 wells for measurement).
[0109] 2. Sample incubation: Cover the 96-well plate with sealing tape to prevent volatilization and contamination of the sample, place the 96-well plate in a mixer (Thermo Mixer C, Eppendorf) away from light, and incubate at 37°C and 300 rpm. In this experiment, the 96-well plate type selected was 96well Costar blk / clrbtm (a 96-well plate produced by Costar for laboratory use, which has a black bottom and a transparent top).
[0110] 3. Fluorescence measurement parameters: Select the fluorescence measurement mode on the M5e multifunctional microplate reader (Molecular Devices, LLC), set the excitation wavelength to 430 nm, the emission wavelength to 470 nm, the measurement temperature to room temperature (about 25°C), and select 96-well Costar blk / clrbtm as the 96-well plate type.
[0111] 4. Sample measurement: Incubate the test sample for the set time for fluorescence measurement, and take the average value of the fluorescence measurement values of 2 replicate wells for data analysis. The initial fluorescence value is the fluorescence measurement value after incubation at 37°C for 1 hour. After taking out the 96-well plate, wrap it with aluminum foil to avoid light.
[0112] 2. Stability inspection
[0113] The stability test is divided into two parts: appearance inspection and peptide content inspection. Appearance inspection is to check the stability of the preparation by visually observing the clarity of the preparation and whether there is visible foreign matter. Peptide content inspection is to check the stability of the preparation by measuring the peptide content by HPLC. Preparations that pass the appearance inspection are selected for accelerated testing in a 25-degree Celsius stability test chamber, and peptide content inspection is performed at each inspection time point.
[0114] Specifically, the relevant inspection steps are:
[0115] 1. Appearance inspection
[0116] Prepare samples according to the requirements of the stability study formula table and store them in a 25 degree Celsius stability test chamber for accelerated testing. Take out each preparation at different time points (such as 14 days, 1 month, 2 months, 3 months, etc.) for appearance inspection. The appearance inspection is to observe the clarity of the preparation, whether there is visible foreign matter formation and other indicators by visual inspection. If no obvious abnormality is observed in the appearance inspection, the preparation meets the requirements and proceed to the next step of HPLC testing. Otherwise, the preparation does not meet the requirements and the next step of testing is not performed.
[0117] 2. Peptide content test
[0118] The preparations for stability study were stored in a 25°C stability test chamber for accelerated testing. At different time points (e.g., 14 days, 1 month, 2 months, 3 months, etc.), the preparations that passed the appearance inspection were tested for peptide content. 100 μL of the preparation was taken as the test sample, and the HPLC method was used to determine the content of GLP-1 and insulin glargine in the preparation to evaluate the stability.
[0119] Specifically,
[0120] The chromatographic column used for detection was: Thermo BioBasic 18 column (250x 4.6mm, 5μm), the detection wavelength was 214nm, and the column temperature was 35℃;
[0121] Mobile phase A was: phosphate (pH 2.5)-sodium chloride-25% acetonitrile,
[0122] Mobile phase B was: phosphate (pH 2.5)-sodium chloride-65% acetonitrile,
[0123] A gradient elution procedure was used, in which the concentration of phase B was gradually increased from 4% to 17% within 20 minutes, and then further increased to 53% within 18 minutes for gradient elution. Under the same chromatographic conditions, a chromatographic spectrum containing only single components of insulin glargine and GLP-1 could be obtained.
[0124] By comparing with the spectra of the single-component preparation containing glargine insulin and GLP-1, the premixed preparations derived from glargine insulin and GLP-1 or its derivatives can be separately attributed. Generally speaking, the retention of glargine insulin and its derivatives on the C18 chromatographic column is relatively weak, and the peak position is in the first half of the chromatogram of the drug preparation, and the retention of GLP-1 or its derivative benaglutide on the C18 chromatographic column is relatively strong, and the peak position is in the second half of the chromatogram of the compound preparation. The GLP-1 peptide content retention (also referred to as "peptide content" or "GLP-1 peptide content" in this article) can be obtained by calculating the ratio of the peak area of GLP-1 at different stability inspection points to the initial value. In other words, at different stability inspection time points, the preparation samples are taken for HPLC analysis to obtain the peak area of the chromatographic peak corresponding to GLP-1. Then the GLP-1 peak area at each stability inspection time point is compared with the GLP-1 peak area at the initial time point (t0) to obtain the percentage of the GLP-1 peptide content. The same method can be used to calculate the glargine insulin peptide content.
[0125] Example 1
[0126] In this example, a series of different preparation compositions containing a GLP-1 receptor agonist were prepared, and the ThT test was used to demonstrate that DDM can significantly inhibit the formation of GLP-1 fibrosis and improve the physical stability of the preparation compositions.
[0127] Preparation compositions 1 to 28 are prepared according to given dosages according to the components listed in the following table, wherein zinc acetate is used as the zinc ion source.
[0128]
[0129]
[0130] After obtaining the above-mentioned formulation compositions 1 to 28, the ThT test listed in the general method was performed to determine the effect of each formulation on physical stability by detecting the formation of fibrils. The schematic results are summarized in Figures 1 to 8 middle.
[0131] Summary of ThT test results
[0132] 1. By analyzing the results of ThT tests on formulation compositions 1 to 4, the inventors found that for the test samples of the glargine insulin / benaglutide stock solution compound preparation, DDM was significantly superior to other surfactants in inhibiting the formation of GLP-1 fibrillation and improving physical stability. Figure 1 The schematic ThT test results of formulation compositions 1 to 4 are shown, i.e., the effects of formulations containing DDM, formulations without surfactant, and formulations containing different surfactants (Tween 20, Tween 80) on physical stability for the test samples of the compound formulation of glargine insulin and benaglutide. Figure 1 As shown in , the inventors found that in the initial stage (<30 hours), the fluorescence increase of each test sample was not obvious. This shows that in the initial stage, no obvious trend of fibril formation was observed in each test sample. As the incubation time was extended to 30 hours, a more obvious increase in fluorescence intensity could be observed in the formulation formulas (formulation compositions 1 to 4) without DDM or containing Tween 20 / Tween 80; as the test time continued to increase, the fluorescence intensity increased rapidly. This shows that there was obvious protein fiber formation in these test samples. However, in the test samples containing DDM, the fluorescence intensity was basically unchanged within the range of the ThT test experiment of nearly 50 hours. This shows that for the test samples of the glargine insulin / benaglutide stock solution compound preparation, DDM is significantly superior to other surfactants in inhibiting the formation of GLP-1 fibrillation and improving physical stability.
[0133] 2. By analyzing the results of the ThT test on formulation compositions 5 to 8, the inventors found that for the benaglutide stock solution test samples, DDM was significantly superior to other surfactants in inhibiting the formation of GLP-1 fibrillation and improving physical stability. Figure 2The schematic ThT test results of formulation compositions 5 to 8 are shown, which compare the effects of formulations containing DDM and formulations without surfactant and with different surfactants (Tween 20, Tween 80) on the physical stability of benaglutide stock solution test samples. Figure 2 As shown in the figure, in the initial stage (<30 hours), the fluorescence increase of each test sample was not obvious. As time went on, the fluorescence intensity increased significantly in the formulations without DDM or containing Tween 20 / Tween 80; in the test samples containing DDM, the fluorescence intensity remained basically unchanged. This shows that for the benaglutide stock solution test samples, DDM is significantly superior to other surfactants in inhibiting the formation of GLP-1 fibrillation and improving physical stability.
[0134] 3. By analyzing the results of the ThT test on the preparation compositions 9 to 12, the inventors found that for the benaglutide preparation test samples, DDM can significantly inhibit the formation of GLP-1 fibrillation and improve the physical stability. Figure 3 The exemplary ThT test results of formulation compositions 9 to 12 are shown, which compare the effects of the benaglutide formulation and the benaglutide formulation test samples containing different concentrations of DDM on the physical stability. Figure 3 As shown in the figure, in the initial stage (<30 hours), the fluorescence increase of each test sample was not obvious. As time went on, the fluorescence intensity of the benaglutide preparation test sample increased significantly; in the benaglutide test samples containing different concentrations of DDM, even if the DDM concentration was as low as 0.01%, the fluorescence intensity remained basically unchanged during the entire THT test process. This shows that for the benaglutide preparation test samples, DDM can significantly inhibit the formation of GLP-1 fibrillation and improve physical stability.
[0135] 4. By analyzing the results of ThT tests on formulation compositions 13 to 17, the inventors found that in formulation systems containing different antibacterial agents, DDM can significantly inhibit the formation of protein fibrillation and improve formulation stability. Figure 4 The schematic ThT test results of formulation compositions 13 to 17 are shown, that is, the effect of DDM on the physical stability of the test samples of the insulin glargine / benaglutide stock solution compound formulation containing different antibacterial agents is compared. Figure 4 As shown in the figure, during the entire test process (>150 hours), the fluorescence intensity of each test sample did not increase significantly. This shows that in the formulation system containing different antibacterial agents, DDM can significantly inhibit the formation of protein fibrillation and improve the stability of the formulation.
[0136] 5. By analyzing the results of ThT tests on formulation compositions 18 to 22, the inventors found that DDM has significant advantages over conventional formulations in inhibiting protein fibrillation and improving formulation stability. Figure 5The schematic ThT test results of formulation compositions 18 to 22 are shown, that is, the THT test results of the test samples of the formulations containing DDM (20201112-1, 20201112-2) and the formulations based on conventional formulations (20201112-3, 20201112-4, 20201112-5) are compared (Table 1 Formulations 18-22). As shown in Figure 5 As shown in the figure, in the three test samples without DDM, the fluorescence of the THT test increased significantly during the test; in the test samples containing DDM, the fluorescence value of the THT test remained basically unchanged. This result shows that DDM is significantly superior to conventional preparations in inhibiting protein fibrillation and improving preparation stability.
[0137] 6. By analyzing the results of ThT tests on formulation compositions 23 to 28, the inventors found that DDM can significantly inhibit the formation of GLP-1 fibrillation and improve the physical stability of GLP-1 and its analogs and dual or multiple agonists based on GLP-1. Figures 6 to 8 The schematic ThT test results of formulation compositions 23 to 28 are shown, namely Figures 6 to 8 The effects of GLP-1 and similar structured peptides (sample number: 988927) and GLP-1 / GIP dual agonists (sample number: P13) on the physical stability of the test samples with and without 0.1% DDM were investigated (Table 1 Formulations 23-28). Figures 6 to 8 As shown in the figure, after incubation at 37°C for 1-2 days, the fluorescence intensity of each test sample without 0.1% DDM was significantly increased; after incubation for 7 days, the fluorescence intensity of GLP-1 and the test sample No. 988927 increased to more than 100 times the initial value, and the fluorescence intensity of the test sample No. P13 increased to more than 35 times the initial value. The fluorescence increase of each test sample containing 0.1% DDM was not obvious within the test time of 1 week. This shows that for GLP-1 and its analogs and dual or multiple agonists based on GLP-1, DDM can significantly inhibit the formation of GLP-1 fibrosis and improve physical stability.
[0138] Example 2
[0139] In this example, a series of different preparation compositions containing a GLP-1 receptor agonist were prepared, and stability tests were performed to demonstrate that DDM can improve the stability of the preparations.
[0140] Preparation compositions A1 to A20 were prepared according to the given dosages according to the components listed in the following table, wherein zinc chloride was used as the zinc ion source.
[0141]
[0142]
[0143] After obtaining the above-mentioned formulation compositions A1 to A20, the stability study listed in the general method is divided into two parts: appearance inspection and peptide content inspection to determine the effect of each formulation formula on physical stability. The schematic results and related analysis are as follows.
[0144] Summary of stability study results
[0145] 1. Through the stability test of the formulation compositions A1 to A4, it can be seen that DDM can significantly increase the stability of the formulations compared with Tween 20 and Tween 80. Specifically, the schematic results of the stability test of the formulation compositions A1 to A4 are summarized as follows:
[0146] Table 1 Stability study results of insulin glargine / benaglutide stock solution compound preparation
[0147]
[0148] Y means the appearance inspection has passed.
[0149] As shown in the table above, the stability test results of the glargine insulin / benaglutide stock solution compound preparations containing DDM, no surfactant and different surfactants (Tween 20, Tween 80) are compared. It can be seen that the preparation without surfactant (preparation composition 1: Lot20200519) has a peptide content reduced to 93.36% after an accelerated test at 25 degrees Celsius for 1 month (25C1M); the preparation containing Tween 20 (preparation composition 2: Lot20200713 / BEM040+GLP11.0_TW20) has a peptide content reduced to 93.84% after an accelerated test at 25 degrees Celsius for 1 month; the preparation containing Tween 80 (preparation composition 3: Lot20200713 / BEM040+GLP1 1.0_TW80) has a gel formation after an accelerated test at 25 degrees Celsius for 14 days (25C14D). The peptide content of the preparation containing 0.1% DDM (preparation composition 4: Lot20200928_4#) in the 3-month accelerated test at 25 degrees Celsius was 94.66%, and the appearance inspection passed. The experimental results show that compared with Tween 20 and Tween 80, DDM can significantly increase the stability of the preparation.
[0150] 2. Through the stability study of the preparation compositions A5 to A9, it can be seen that DDM can improve the stability of the preparations compared with conventional excipients. Specifically, the schematic results of the stability study of the preparation compositions A5 to A9 are summarized as follows:
[0151] Table 2 Stability study results of insulin glargine / benaglutide stock solution compound preparation
[0152]
[0153] Y means the appearance inspection has passed.
[0154] As shown in the table above, the results of stability studies on preparations containing DDM and preparations in combination with conventional excipients are summarized (preparation compositions A5 to A9). Preparations formed with different combinations of glycerol, mannitol, and propylene glycol (preparation compositions A7 to A9) failed the appearance inspection in the 25-degree Celsius accelerated stability test. In addition, the inventors found that lowering the pH value may be beneficial to improving the physical stability of the preparation and avoiding abnormal appearance. However, when the pH value is lowered, the peptide content of the preparation based on conventional excipients in the 25-degree Celsius 3-month accelerated stability test (25C3M) is about 90%, while the peptide content of the compound preparation containing DDM in the 25-degree Celsius 3-month accelerated stability test can be greater than 94%. The experimental results show that compared with conventional excipients, DDM can significantly improve the stability of the preparation.
[0155] 3. Through the stability study of the preparation compositions A10 to A14, it can be seen that DDM can improve the stability of the preparations and is compatible with the antibacterial agents commonly used in injections. Specifically, the schematic results of the stability study of the preparation compositions A10 to A14 are summarized as follows:
[0156] Table 3 Stability study results of insulin glargine / benaglutide stock solution compound DDM preparations containing different antibacterial agents
[0157]
[0158] As shown in the table above, the stability test results of preparations containing DDM and different antibacterial agents are summarized. The antibacterial agents commonly used in injection-grade preparations, such as phenol, m-cresol and benzyl alcohol, have been tested. Preparations containing DDM have not failed the appearance inspection through the accelerated stability test at 25 degrees Celsius for 3 months, and the peptide content is greater than 92%. The experimental results show that DDM can not only significantly improve the stability of the preparation, but also is compatible with antibacterial agents commonly used in injections.
[0159] 4. The stability of the preparation compositions A15 to A18 was investigated and the results of the stability investigation of the preparations with different concentrations of DDM were compared. The results are summarized as follows:
[0160] Table 4 Stability study results of insulin glargine / benaglutide stock solution compound preparations containing different concentrations of DDM
[0161]
[0162] As shown in the table above, the effect of DDM concentration on the stability of premixed preparations is summarized. The accelerated stability test of the premixed preparation containing 0.05% DDM at 25 degrees Celsius for 2 months (25C60D) failed the appearance inspection. This shows that the improvement of the stability of the preparation by 0.05% DDM cannot meet the requirements of accelerated stability. When the DDM concentration in the premixed preparation is increased to more than 0.1%, the accelerated stability test at 25 degrees Celsius for 3 months (25C90D) did not fail the appearance inspection, and the peptide content was greater than 93%. This shows that DDM concentrations above 0.1% are preferred, which can improve the physical stability of the preparation to a greater extent, thereby meeting the requirements of the stability of the premixed preparation.
[0163] 5. The stability of the formulation compositions A16, A19 and A20 was investigated, and the stability of the formulations containing DDM at different pH values was compared. The results are shown below:
[0164] Table 5 Stability study results of insulin glargine / benaglutide stock solution compound DDM preparations at different pH values
[0165]
[0166] As shown in the table above, the effect of formulation pH on the stability of premixed formulations is summarized (Table 2 Formulations 16, 19, 20). In the range of formulation pH 4.0-4.5, the premixed formulations containing 0.1% DDM did not fail the appearance inspection in the 3-month accelerated stability test at 25 degrees Celsius, and the peptide content was greater than 93%. The experimental results show that DDM can effectively improve the stability of the formulation within the range of pH 4.0-4.5.
[0167] In the description of this specification, the description with reference to the terms "one embodiment", "some embodiments", "examples", "specific examples", or "some examples" means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representation of the above terms does not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described may be combined in any one or more embodiments or examples in a suitable manner.
[0168] Although the embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and are not to be construed as limitations on the present invention. A person skilled in the art may change, modify, replace and modify the above embodiments within the scope of the present invention without departing from the principles and purpose of the present invention.
Claims
1. A pharmaceutical composition, characterized in that contain: an active ingredient, the active ingredient comprising a GLP-1 receptor agonist; and The surfactant comprises an alkyl glycoside compound.
2. The pharmaceutical composition according to claim 1, characterized in that The active ingredient further comprises insulin or an insulin analog, and optionally, the insulin analog comprises at least one of insulin lispro, insulin aspart, insulin glulisine, insulin glargine, insulin degludec and insulin detemir, Optionally, based on the total weight of the pharmaceutical composition, the pharmaceutical composition contains 0.1 to 1 wt % of the insulin or insulin analog; optionally, it contains 0.1 to 0.4 wt % of the insulin or insulin analog.
3. The pharmaceutical composition according to claim 1, characterized in that The alkyl glycoside compound contains: A sugar group, wherein the sugar group includes at least one selected from the group consisting of glucose, maltose, sucrose and trehalose; An alkyl chain containing 10 to 16 carbon atoms; A linking group, wherein the linking group is used to connect the sugar group and the alkyl chain, and the linking group includes at least one selected from a glycosidic bond, a thioglycosidic bond, and an amide bond.
4. The pharmaceutical composition according to claim 3, characterized in that The alkyl chain contains 10 to 14 carbon atoms.
5. The pharmaceutical composition according to claim 3, characterized in that The sugar group includes maltose or sucrose.
6. The pharmaceutical composition according to claim 1, characterized in that The alkyl glycoside compound includes at least one of n-dodecyl β-D-maltoside and sucrose monododecanoate, preferably n-dodecyl β-D-maltoside. Optionally, based on the total weight of the pharmaceutical composition, the pharmaceutical composition contains 0.05 to 0.50 weight % of the alkyl glycoside compound, preferably 0.1 to 0.20 weight % of the alkyl glycoside compound.
7. The pharmaceutical composition according to claim 1, characterized in that The GLP-1 receptor agonist is a polypeptide agonist.
8. The pharmaceutical composition according to claim 7, characterized in that The GLP-1 receptor agonist also has the function of a GIP agonist.
9. The pharmaceutical composition according to claim 7, characterized in that The GLP-1 receptor agonist comprises at least one selected from the following: GLP-1, GLP-1 analogs or derivatives thereof; An extended GLP-1 fragment or an analog or derivative thereof; and Truncated GLP-1 fragments or analogs or derivatives thereof.
10. The pharmaceutical composition according to claim 7, characterized in that The GLP-1 analogs include Exendin-4.
11. The pharmaceutical composition according to claim 1, characterized in that The GLP-1 receptor agonist includes at least one selected from the following: liraglutide, exenatide, lixisenatide, albiglutide, benaglutide, dulaglutide, semaglutide, pepramotetide, telportide, preferably benaglutide.
12. The pharmaceutical composition according to claim 1, characterized in that The active ingredients include benaglutide and insulin glargine.
13. The pharmaceutical composition according to any one of claims 1 to 12, characterized in that The pharmaceutical composition is a liquid preparation, preferably a premixed aqueous injection preparation.
14. The pharmaceutical composition according to claim 13, characterized in that The pharmaceutical composition contains an antibacterial agent. Optionally, the antibacterial agent includes at least one of a phenolic compound, an aromatic alcohol compound, phenoxyethanol and a chlorohydrin compound. Preferably, the antibacterial agent includes at least one of phenol, m-cresol, benzyl alcohol, phenoxyethanol and chlorobutanol.
15. The pharmaceutical composition according to claim 14, characterized in that The pharmaceutical composition contains 0.1 to 10 mg / mL of the GLP-1 receptor agonist.
16. The pharmaceutical composition according to claim 14, characterized in that The pH of the liquid preparation is 3.0-9.0, Optionally, the insulin analog is insulin glargine, and the pH of the liquid preparation is 3.0 to 5.
0. Optionally, the pH of the liquid preparation is 4.0 to 4.
5. Optionally, the insulin analog is aspart insulin, and the pH of the liquid preparation is 7.0 to 9.
0.
17. The pharmaceutical composition according to claim 14, characterized in that The pharmaceutical composition further contains zinc ions, Optionally, the concentration of the zinc ions is 1 to 100 micrograms / ml, optionally, 10 to 50 micrograms / ml, optionally, 20 to 40 micrograms / ml.
18. The pharmaceutical composition according to claim 1, characterized in that The pharmaceutical composition further contains a solubilizing agent, which includes at least one selected from the group consisting of glycerol, mannitol and propylene glycol, and the content of the solubilizing agent is 10 to 50 mg / ml based on the total volume of the pharmaceutical composition; preferably, the solubilizing agent is selected from glycerol, and the content of the glycerol is 10 to 25 mg / ml based on the total volume of the pharmaceutical composition, or The pharmaceutical composition does not contain any one selected from the following: polysorbate 20, polysorbate 80, poloxamer 188, hydroxypropyl beta-cyclodextrin and amino acid. Optionally, the surfactant only includes the alkyl glycoside compound.
19. The pharmaceutical composition according to claim 1, characterized in that The pharmaceutical composition does not form foreign matter in an accelerated stability test at 25 degrees Celsius for 3 months, and the peptide content is not less than 93%.
20. A method for improving the storage stability of a pharmaceutical composition, wherein the pharmaceutical composition contains a GLP-1 receptor agonist, characterized in that: The method comprises adding an alkyl glycoside compound to the pharmaceutical composition.
21. The method according to claim 20, characterized in that The pharmaceutical composition further comprises insulin or an insulin analog, and optionally, the insulin analog comprises at least one of insulin lispro, insulin aspart, insulin glulisine, insulin glargine, insulin degludec and insulin detemir.
22. The method according to claim 20, characterized in that The alkyl glycoside compound includes at least one of n-dodecyl β-D-maltoside (DDM) and sucrose monododecanoate, preferably n-dodecyl β-D-maltoside (DDM).
23. Use of the pharmaceutical composition according to any one of claims 1 to 19 in the preparation of a drug, wherein the drug is used for: (i) prevention and / or treatment of diabetes, and / or for reducing HbA1C; (ii) delaying or preventing the progression of diabetes, delaying the progression of impaired glucose tolerance to insulin-requiring type 2 diabetes, delaying or preventing insulin resistance, and / or delaying the progression of insulin-not-requiring type 2 diabetes to insulin-requiring type 2 diabetes; (iii) improving β-cell function, and / or restoring β-cell glucose sensitivity; (iv) prevention and / or treatment of eating disorders; reduction of gastric motility; delay of gastric emptying; (v) prevention and / or treatment of comorbidities of obesity; (vi) prevention and / or treatment of diabetic complications; and / or (vii) prevention and / or treatment of cardiovascular diseases.
Citation Information
Cited By
Pharmaceutical compositions and their uses, and methods for improving the storage stability of pharmaceutical compositions
WO2025232124A1
